Across the whole pharma sector, there are four or five stocks big one out there which are going to gain market share. So, CDMO is one space within pharma which should do well as we go along. But pharma as a whole space per se has been doing okay and we continue to believe that incrementally also pharma should continue to do well in the coming year also.
Tata Communications Q1 Results: Cons PAT falls 43% YoY to Rs 190 crore, revenue up 7%
Tata Communications reported a 43% YoY drop in Q1FY26 net profit at Rs 190 crore. Revenue rose 7% to Rs 5,960 crore. Sequentially, profit plunged
July 17, 2025